Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease

American Journal of Gastroenterology

Volumn 94, Issue 4, 1999, Pages 884-887

  Schenk, B E ^a   Kuipers, E J ^a   Klinkenberg Knol, E C ^a   Eskes, S A ^a   Meuwissen, S G M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ENDOSCOPY; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REMISSION; STOMACH PH;

ANTI-ULCER AGENTS; CASE-CONTROL STUDIES; ESOPHAGITIS, PEPTIC; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0033118743     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00037-4     Document Type: Article

References (28)

1. Ruiz B, Correa P, Fontham ETH, et al. Antral atrophy, Helicobacter pylori colonization and gastric pH. Am J Clin Pathol 1996;105:96-101.
2. Verdu EF, Armstrong D, Idström J-P, et al. Intragastric pH during treatment with omeprazole: Role of Helicobacter pylori and H. pj7ori-associated gastritis. Scand J Gastroenterol 1996; 31:1151-6.
3. Verdu EF, Armstrong D, Fräser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995;36:539-43.
4. Verdu EF, Armstrong D, Idström J-P, et al. Effect of curing Helicobacter pylori on intragastric pH during treatment with omeprazole. Gut 1995:37:743-8.
5. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH raising effect of omeprazole in duodenal ulcer patients. Gastroenterology 1995;! 10:725-32.
6. Labenz J, Tillenberg B, Peitz U, et al. Effect of curing H. pylori infection on 'intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut 1997;41:33-6.
7. Savary M, Miller G. The esophagus. Switzerland: Solothurn, 1977.
8. Price AB. The Sydney System: Histological division. J Gastroenterol Hepatol 1991;6:209-22.
9. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophie gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 96;334:1018-22.
10. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori associated corpus gastritis during acid suppressive therapy: Implications for long-term safety. Am J Gastroenterol 1995;90:1401-6.
11. Logan RPH, Walker MM, Misiewicz JJ, et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995;36:12-6.
12. Solcia E, Villani L, Fiocca R, et al. Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol 1994;29(suppl 201):28-34.
13. McGowan CC, Cover TL, Blaser MJ. H. pylori and gastric acid: biological and therapeutic implications. Gastroenterology 1996;110:926-38.
14. Sachs G. Gastritis H. pylori and proton pump inhibitors. Gastroenterology 1997;! 12:1033-6.
15. Werdmuller BFM, Loffeld RJLF. Helicobacter pylori has no role in the pathogenesis of reflux oesophagitis. Dig Dis Sci 1997;42:103-5.
16. Mihara M, Haruma K, Kamada K, et al. Low prevalence of/J. pylori infection in patients with reflux oesophagitis. Gut 1996; 39(suppl 2):A94.
17. Sacca N, De medici A, Rodino S, et al. Reflux oesophagitis: A complication of Helicobacter pylori eradication therapy? Gut 1 1996;39(suppl 2):A91.
18. Labenz J, Tillenburg B, Peitz U, et al. Long-term consequences of Helicobacter pylori eradication: Clinical aspects. Scand J Gastroenterol 1996;31(suppl 215):lll-5.
19. El Seraq HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gastroenterology 1997;112:A113.
20. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998;58:588-90.
21. Hassall E. Barren's esophagus: Congenital or acquired? Am J Gastroenterol 1993;88:819-24.
22. Schnell JW, Vicari JJ, Perez-Perez GI, et al. H. pylori cagAnegative strains predominate in gastroesophageal reflux disease, Barren's esophagus, and esophageal dysplasia/adenocarcinoma. Gastroenterology 1997;112:A283.
23. Kuipers EJ, Pérez-Pérez GI, Meuwissen SGM, et al. Helicobacter pylori and atrophie gastritis; importance of the cagA status. J Natl Cancer Inst 1995;87:1777-80.
24. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Int Med 1994;121:161-7.
25. Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci 1991;36:552-7.
26. Solcia E, Fiocca R, Havu N, et al. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992;51(suppl l):82-92.
27. Eissele R, Brunner G, Simon B, et al. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil-cell hyperplasia. Gastroenterology 1997; 112:707-17.
28. Lundell L, Havu N, Andersson A, et al. Gastritis development and acid suppression therapy revisited: Results of a randomized clinical study with long-term follow-up. Gastroenterology 1997;112:A128.